Sector
PharmaceuticalsOpen
₹187.5Prev. Close
₹187.31Turnover(Lac.)
₹339.89Day's High
₹195.25Day's Low
₹183.452 Week's High
₹369.752 Week's Low
₹156.01Book Value
₹90.13Face Value
₹10Mkt Cap (₹ Cr.)
930.27P/E
26.9EPS
6.95Divi. Yield
1.6Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 48.21 | 48.21 | 48.21 | 43.25 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 368.66 | 347.38 | 330.51 | 203.6 |
Net Worth | 416.87 | 395.59 | 378.72 | 246.85 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 204.52 | 222.83 | 179.29 | 153.69 |
yoy growth (%) | -8.21 | 24.28 | 16.65 | -15.33 |
Raw materials | -127.82 | -137.74 | -101.16 | -91.24 |
As % of sales | 62.5 | 61.81 | 56.42 | 59.36 |
Employee costs | -21.05 | -18.33 | -20.02 | -18.33 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 16.16 | 32.7 | 15.73 | 6.96 |
Depreciation | -4.32 | -4.1 | -3.47 | -3.22 |
Tax paid | -4.42 | -9.23 | -4.51 | -2.25 |
Working capital | 53.98 | -10.52 | 14.2 | -0.58 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -8.21 | 24.28 | 16.65 | -15.33 |
Op profit growth | -48.96 | 30.3 | 158.76 | -48.38 |
EBIT growth | -47.64 | 68.3 | 59.58 | -41.25 |
Net profit growth | -49.96 | 109.2 | 138.37 | -44.65 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 614.59 | 550.99 | 477.52 | 491.81 | 359.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 614.59 | 550.99 | 477.52 | 491.81 | 359.5 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 14.61 | 3.07 | 10.6 | 17.99 | 0.63 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Vice Chairman
Surendra Somani
Company Sec. & Compli. Officer
Sunil Sodhani
Independent Director
Siddhan Subramanian
Independent Director
Sunita Banerji
Independent Director
Mamta Biyani
Independent Director
Narayan Atal
Chairman (Non-Executive)
Susheel Somani
Non Executive Director
Adarsh Somani
Non Executive Director
Varun Somani
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kopran Ltd
Summary
Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility.Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the worlds highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US.Koprans bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Koprans high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June
Read More
The Kopran Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹192.66 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kopran Ltd is ₹930.27 Cr. as of 02 Apr ‘25
The PE and PB ratios of Kopran Ltd is 26.9 and 2.18 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Kopran Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kopran Ltd is ₹156.01 and ₹369.7 as of 02 Apr ‘25
Kopran Ltd's CAGR for 5 Years at 51.85%, 3 Years at -14.03%, 1 Year at -30.73%, 6 Month at -43.74%, 3 Month at -11.94% and 1 Month at 9.23%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.